Immunome says FDA clears IND for IM-1340 solid tumor ADC
IMNM•The FDA cleared Immunome’s IND for IM-1340, an antibody-drug conjugate for advanced solid tumors. A Phase 1 trial is slated to start in Q4 2026 to assess safety, pharmacokinetics and early anti-tumor activity.
1. Trial plans
Immunome said the FDA cleared its IND for IM-1340, which it describes as a first-in-class antibody-drug conjugate for advanced solid tumors. The Phase 1 trial is slated to start in Q4 2026 and will assess safety, pharmacokinetics and early anti-tumor activity; IM-1340 uses Immunome’s proprietary HC74 topoisomerase I inhibitor payload.
